Trending...
- Virtual Workplace Platform Developer REACH Expands Executive Team, Positioning the Company to Drive International Growth
- Key Risk Names Whitney Neal as Vice President, Human Resources
- Fathym announces the addition of Sergio Sotolongo to its board of directors
DURHAM, N.C., May 27, 2022 /PRNewswire/ -- Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Pemetrexed Lyo. Injection to its line of chemotherapy drugs. The new drug is formulated as a sterile lyophilized (freeze-dried) powder to be reconstituted for intravenous infusion. Pemetrexed Lyo. Injection is therapeutically equivalent to Eli Lilly and Company's ALIMTA® and approved to treat Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Malignant Pleural Mesothelioma (MPM), a cancer of the inside lining of the chest cavity.1 Accord's product is offered in vials of 100mg, 500mg, and 1000mg strengths and is currently available to ship.
Pemetrexed Lyo. Injection is FDA-approved for use as a first-line treatment for locally advanced or metastatic NSCLC with non-squamous tissue type, a maintenance drug for metastatic NSCLC, a treatment for NSCLC that recurs after prior chemotherapy, and a treatment for MPM in patients whose cancer can't be removed surgically.2
"Accord Healthcare US has distinguished itself in oncology injectables, and the introduction of Pemetrexed Lyo. Injection to our portfolio strengthens our offering of oncology medications," said Accord CEO Jeff Hampton. "We are committed to making more generics available to patients. Our technical capabilities and manufacturing infrastructure have defined our company's history and the patients shape our future."
More on ncarol.com
Important Safety Information: Pemetrexed Lyo. Injection may cause fatigue or nausea and vomiting. Other possible side effects are serious, including fast heartbeat, chest pain, blistering and other skin reactions, and difficulty breathing. Pemetrexed is in a class of medications called antifolate antineoplastic agents and works by blocking the action of a certain substance in the body that may help cancer cells multiply.2
Further information about safety and potential side effects can be found in our product insert.
Pemetrexed was approved by the FDA for the treatment of Malignant Pleural Mesothelioma.3 For more information, please visit the Products page at Accord Healthcare US.
About Accord Healthcare US
Accord Healthcare, a wholly owned subsidiary of Intas Pharmaceuticals, is a leading generic pharmaceutical company. Accord is committed to improving lives by increasing access to medicines while also providing novel solutions that enhance the pharmaceutical experience for both healthcare providers and patients. Accord Healthcare combines its advanced manufacturing technology with in-house research to produce highly complex, affordable, and essential medicines. Accord Healthcare's forward-thinking, innovative approach, and its resolve to help patients remains at the heart of everything they do. Accord is headquartered in Durham, North Carolina. The Intas network markets its products in 80 countries. To learn more, visit the Accord website.
More on ncarol.com
References
1 Access data FDA.gov. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021462s021lbl.pdf. Accessed May 2022.
2 Pemetrexed Injection, National Library of Medicine, MedlinePlus. Available at: https://medlineplus.gov/druginfo/meds/a607043.html. Accessed May 2022.
3 FDA drug approval summaries: pemetrexed (Alimta), U.S. Food and Drug Administration. Available at: https://pubmed.ncbi.nlm.nih.gov/15477632/. Accessed May 2022.
Media Contact:
Kellyann Zuzulo
Em-Press Media
[email protected]
215.287.7291
SOURCE Accord Healthcare, Inc.
Pemetrexed Lyo. Injection is FDA-approved for use as a first-line treatment for locally advanced or metastatic NSCLC with non-squamous tissue type, a maintenance drug for metastatic NSCLC, a treatment for NSCLC that recurs after prior chemotherapy, and a treatment for MPM in patients whose cancer can't be removed surgically.2
"Accord Healthcare US has distinguished itself in oncology injectables, and the introduction of Pemetrexed Lyo. Injection to our portfolio strengthens our offering of oncology medications," said Accord CEO Jeff Hampton. "We are committed to making more generics available to patients. Our technical capabilities and manufacturing infrastructure have defined our company's history and the patients shape our future."
More on ncarol.com
- WELL Health Adds New Executives to Drive Continued Growth
- Emily "Ellie" Spencer joins Spencer Properties full time!
- Indie Brand Vow Beauty Enters Walmart
- North Carolina: Governor Cooper Signs Three Bills into Law
- James Postrasija, CEO of Order Food Online on Platform Features/Benefits
Important Safety Information: Pemetrexed Lyo. Injection may cause fatigue or nausea and vomiting. Other possible side effects are serious, including fast heartbeat, chest pain, blistering and other skin reactions, and difficulty breathing. Pemetrexed is in a class of medications called antifolate antineoplastic agents and works by blocking the action of a certain substance in the body that may help cancer cells multiply.2
Further information about safety and potential side effects can be found in our product insert.
Pemetrexed was approved by the FDA for the treatment of Malignant Pleural Mesothelioma.3 For more information, please visit the Products page at Accord Healthcare US.
About Accord Healthcare US
Accord Healthcare, a wholly owned subsidiary of Intas Pharmaceuticals, is a leading generic pharmaceutical company. Accord is committed to improving lives by increasing access to medicines while also providing novel solutions that enhance the pharmaceutical experience for both healthcare providers and patients. Accord Healthcare combines its advanced manufacturing technology with in-house research to produce highly complex, affordable, and essential medicines. Accord Healthcare's forward-thinking, innovative approach, and its resolve to help patients remains at the heart of everything they do. Accord is headquartered in Durham, North Carolina. The Intas network markets its products in 80 countries. To learn more, visit the Accord website.
More on ncarol.com
- Disney Good Neighbor Hotel Lulu is Open for the Summer
- EPA's Renewable Fuel Standard Pathways Expand to Include Greasezilla® Advanced Biofuel as RIN-Qualified Feedstock
- Aspiring To Excellence Continues at Globe Star with CARF Accreditation
- JKS Financial Sponsors Program To Teach High School Students Investment Skills
- Gary Kevin Coats Raleigh, NC Top 10 Tips for Homebuyers
References
1 Access data FDA.gov. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021462s021lbl.pdf. Accessed May 2022.
2 Pemetrexed Injection, National Library of Medicine, MedlinePlus. Available at: https://medlineplus.gov/druginfo/meds/a607043.html. Accessed May 2022.
3 FDA drug approval summaries: pemetrexed (Alimta), U.S. Food and Drug Administration. Available at: https://pubmed.ncbi.nlm.nih.gov/15477632/. Accessed May 2022.
Media Contact:
Kellyann Zuzulo
Em-Press Media
[email protected]
215.287.7291
SOURCE Accord Healthcare, Inc.
Filed Under: Business
0 Comments
Latest on ncarol.com
- Go-Forth Pest Control Named to 2022 List of Great Employers to Work for in North Carolina
- Mutual Aid Ambulance Service Partners with Excela Health for Paramedic Training Program
- In2Scuba Diving Co. of Maui introduces its exclusive beginner scuba diving lessons
- Always Ontime: Chaos City - Super Hero Graphic Novel with Neal Adams Cover Launches from Panopolis Metaverse
- New Hampshire Becomes the 15th State to Require Personal Finance as a Core Academic Subject
- Virtual Workplace Platform Developer REACH Expands Executive Team, Positioning the Company to Drive International Growth
- Amwins Partners with FusionMGA Providing Exclusive Access to Strategic Cyber Capacity
- Health Advisory: Protecting Yourself and Others from Monkeypox
- Piedmont Lithium and Sayona Mining Formalize Restart Plans for North American Lithium in Quebec
- Kindle FREE June 28-29: Powerful new memoir from Santa Molina-Marshall poised to help heal abuse victims through inspiring storytelling
- GoodLoan.io announces new program to unlock up to $500,000 for Home Equity Investment
- Beck Properties Group Hires Professional Marketing Team
- Cosplay Universe" Documentary to Premiere at Anime Expo & in Theaters this Summer
- Kano Laboratories, Makers of Kroil, Announces Refreshed Branding for Extended Line of Industrial Product Solutions
- Fathym announces the addition of Sergio Sotolongo to its board of directors
- Key Risk Names Whitney Neal as Vice President, Human Resources
- Prolific Author Tam R. Luc Celebrates Positive Title IX Achievements and Pushes Businesswomen to the Next Level with Boss Up Summit
- Avion Medical Skin Centres to offer innovative treatment for non-melanoma skin cancer patients
- Medical and Dental SEO Specialists 2022 award
- Launch of Def Leppard beauty collection creating Hysteria in the makeup industry